Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease
source: American Journal of Preventive Medicine
year: 2016
authors: Carroll CP, Lanzkron S, Haywood C Jr, Kiley K, Pejsa M, Moscou-Jackson G, Haythornthwaite JA, Campbell CM
summary/abstract:Chronic opioid therapy (COT) for chronic non-cancer pain is frequently debated, and its effectiveness is unproven in sickle cell disease (SCD). The authors conducted a descriptive study among 83 adult SCD patients and compared the severity of disease and pain symptoms among those who were prescribed COT (n=29) with those who were not using COT. All patients completed baseline laboratory pain assessment and questionnaires between January 2010 and June 2014. Thereafter, participants recorded daily pain, crises, function, and healthcare utilization for 90 days using electronic diaries. Analyses were conducted shortly after the final diary data collection period. Patients on COT did not differ on age, sex, or measures of disease severity. However, patients on COT exhibited greater levels of clinical pain (particularly non-crisis); central sensitization; and depression and increased diary measures of pain severity, function, and healthcare utilization on crisis and non-crisis diary days, as well as a greater proportion of days in crisis. Including depressive symptoms in multivariate models did not change the associations between COT and pain, interference, central sensitization, or utilization. Additionally, participants not on COT displayed the expected positive relationship between central sensitization and clinical pain, whereas those on COT demonstrated no such relationship, despite having both higher central sensitization and higher clinical pain. Overall, the results point out a high symptom burden in SCD patients on COT, including those on high-dose COT, and suggest that nociceptive processing in SCD patients on COT differs from those who are not.
organization: Johns Hopkins University School of Medicine, BaltimoreDOI: 10.1016/j.amepre.2016.02.012
read more full text
+myBinderRelated Content
-
Transfusion-Induced iron overloadThe human body has no active mechanism f...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
Long-term opioids may not be best pain management option for all sickle cell patientsSmall study shows some on opioids report...
-
Sickle cell pain in the emergency departmentSickle cell disease is characterized by ...
-
Mental Health Resources for Black, Indigenous and People of Color (BIPOC)In addition to COVID-19, recent events h...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
-
Scientists edit genome to cure sickle cell anemiahttps://www.youtube.com/watch?v=4LKzM3G6...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.